Relypsa, Inc. clinical trials

Acquired by CSL Limited, Aug 9, 2022 · source ↗

The registry lists 7 studies whose lead sponsor is Relypsa, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 3, 2021.

Before and after it joined CSL Limited

First submitted before Relypsa, Inc. became part of CSL Limited: 7
First submitted after Relypsa, Inc. became part of CSL Limited: 0
Unclear, or no submission date: 0

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

Status

Completed: 6
Terminated: 1

Phase

Phase 2: 5
Phase 4: 1
Phase 3: 1

Where

Georgia: 5
United States: 5
Croatia: 3
Slovenia: 3
Hungary: 3
Ukraine: 3

Registry sponsor names on this page

Relypsa, Inc.7 studies

Something wrong with this grouping? Tell us on the CSL Limited page.

Studies

Recruiting first, then most recently updated. Showing 7 of 7. All CSL Limited studies →

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)CompletedNCT01810939Phase 3
Sponsor listed in the registry: Relypsa, Inc. · First submitted before Relypsa, Inc. became part of CSL Limited
Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)CompletedNCT01371747Phase 2
Sponsor listed in the registry: Relypsa, Inc. · First submitted before Relypsa, Inc. became part of CSL Limited
Evaluation of Patiromer in Heart Failure PatientsCompletedNCT00868439Phase 2
Sponsor listed in the registry: Relypsa, Inc. · First submitted before Relypsa, Inc. became part of CSL Limited
Patiromer With or Without Food for the Treatment of HyperkalemiaCompletedNCT02694744Phase 4
Sponsor listed in the registry: Relypsa, Inc. · First submitted before Relypsa, Inc. became part of CSL Limited
Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney DiseaseCompletedNCT03071263Phase 2
Sponsor listed in the registry: Relypsa, Inc. · First submitted before Relypsa, Inc. became part of CSL Limited
An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on HemodialysisTerminatedNCT02033317Phase 2
Sponsor listed in the registry: Relypsa, Inc. · First submitted before Relypsa, Inc. became part of CSL Limited
Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney DiseaseCompletedNCT01130597Phase 2
Sponsor listed in the registry: Relypsa, Inc. · First submitted before Relypsa, Inc. became part of CSL Limited